
Metagenomi Inc (MGX) Stock Forecast & Price Target
Metagenomi Inc (MGX) Analyst Ratings
Bulls say
Metagenomi Therapeutics Inc is focused on developing advanced genomic editing technologies aimed at creating curative treatments for various disorders, with a robust pipeline addressing conditions such as Hemophilia A and cardiovascular diseases. The company’s gene editing approach has demonstrated strong efficacy, achieving durable FVIII levels of 80% over a 19-month period in non-human primates, highlighting the potential for effective long-term treatment solutions. Furthermore, Metagenomi's dual strategy of advancing its pipeline while exploring technology out-licensing for ex vivo cell therapy positions it favorably within the expanding genetic therapeutics market.
Bears say
Metagenomi Therapeutics reported a substantial net loss of $19.9 million in its second quarter of 2025, equating to a loss of $0.54 per share. The company’s stock trades significantly below its cash value, suggesting potential for upside; however, this valuation is undercut by significant operational risks, including possible delays in clinical assessments and unfavorable clinical outcomes from trials for key candidates such as Hemophilia A and TTR. Additionally, there is an ongoing concern regarding potential long-term dilution, adding to the uncertainties surrounding the company's future financial performance.
This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.
Metagenomi Inc (MGX) Analyst Forecast & Price Prediction
Start investing in Metagenomi Inc (MGX)
Order type
Buy in
Order amount
Est. shares
0 shares